Skip to main content

Mirna Publishes Data on Delivery of miRNA Mimics

Premium

Mirna Therapeutics said this week that it has published data in Molecular Therapy showing that a neutral lipid emulsion can be used to systemically deliver tumor-suppressing microRNA mimics and reduce tumor burden in mouse lungs.

In the paper, researchers from Mirna and Yale University used a transgenic mouse model of lung cancer to show that intravenous administration of the lipid-formulated mimics of miR-34 and let-7 triggered an RNAi response in cancer cells and inhibited tumor growth.

“The successful therapeutic delivery of our miRNA mimics in a clinically relevant tumor model is an important milestone in bringing therapeutic miRNAs to the clinic,” Mirna President and CEO Paul Lammers said in a statement. “These data add to the increasing body of evidence that our technology can be applied in a therapeutic context.”

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.